Acquired Company
Tectonic Therapeutic, Inc. completed its merger with AVROBIO, Inc. on June 20, 2024, and the combined company trades on Nasdaq under the ticker TECX.
AVROBIO's vision is to bring personalized gene therapy to the world. The company aims to prevent, halt or reverse disease throughout the body with a single dose of gene therapy designed to drive durable expression of therapeutic protein, even in hard-to-reach tissues and organs including brain, muscle and bone. Its ex vivo lentiviral gene therapy pipeline includes clinical programs in Fabry disease, Gaucher disease type 1 and cystinosis, as well as preclinical programs in Hunter syndrome, Gaucher disease type 3 and Pompe disease. AVROBIO is powered by its industry leading plato® gene therapy platform, its foundation designed to deliver gene therapy worldwide. The company is headquartered in Cambridge, Mass., with an office in Toronto, Ontario. Show more
Location: | Website: www.avrobio.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
0.00
52 Wk Range
$N/A - $N/A
Previous Close
$N/A
Open
$N/A
Volume
N/A
Day Range
$N/A - $N/A
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Insider Ownership
0.00%
Institutional Own.
0.00%
Qtr Updated
06/30/24
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
AVR-RD-05 Details Mucopolysaccharidoses, Mucopolysaccharidosis type II, Rare diseases, Rare genetic disease, Genetic disorder | Failed Discontinued | |
AVR-RD-04 Details Cystinosis | Failed Discontinued | |
AVR-RD-01 Details Genetic disorder, Fabry disease | Failed Discontinued | |
AVR-RD-02 Details Gaucher disease | Failed Discontinued |
